ProfessorJamie Triccas

Jamie Triccas is a bacteriologist who uses a multidisciplinary approach to define immunity to chronic bacterial pathogens and develop new treatments to control infection. He is a Professor of Medical Microbiology and Group Leader in the Infection, Immunity and Inflammation Theme in the School of Medical Sciences at the University of Sydney and is Deputy Director, Sydney Infectious Diseases Institute (Sydney ID). He has over 25 years’ experience working with pathogens and has published widely on aspects of bacterial pathogenesis, immunity to infection and vaccine development/testing (119 peer-reviewed career publications, over 7700 citations). He leads the recently established vaccine consortium comprising the University of Sydney, ExcellGene and Bharat Biotech, supported by supported by the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a broadly protective SARS-CoV-2 vaccine. He is also a Principal Investigator on the Advancing Vaccine Adjuvant Research for Tuberculosis (AVAR-T) contract, a 5-year program funded by the NIH to identify the most promising adjuvant-TB immunogen candidates for clinical development and define immune correlates of protection.